Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTIC CTI BioPharma	$9.09	$9.06	$4.01 ▼ $9.10	$1.20B	0.83	4.50 million shs	N/A
CYTK Cytokinetics	$32.43 -0.9%	$34.40	$29.31 ▼ $61.38	$3.87B	0.59	1.54 million shs	2.41 million shs
NUVL Nuvalent	$75.00 -0.7%	$73.99	$55.54 ▼ $113.51	$5.39B	1.34	493,930 shs	558,997 shs
VRNA Verona Pharma PLC American Depositary Share	$94.32 +3.7%	$74.68	$14.14 ▼ $94.45	$8.03B	0.21	1.32 million shs	1.09 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTIC CTI BioPharma	0.00%	0.00%	0.00%	0.00%	0.00%
CYTK Cytokinetics	0.00%	-5.67%	+6.36%	-28.62%	-37.56%
NUVL Nuvalent	0.00%	-4.14%	+2.42%	-3.80%	-3.97%
VRNA Verona Pharma PLC American Depositary Share	0.00%	+2.30%	+29.76%	+41.18%	+508.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	4.2029 of 5 stars	4.5	3.0	0.0	4.6	1.5	0.8	0.0
NUVL Nuvalent	2.1918 of 5 stars	3.5	2.0	0.0	0.0	1.5	3.3	0.0
VRNA Verona Pharma PLC American Depositary Share	2.1129 of 5 stars	2.5	3.0	0.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTIC CTI BioPharma	0.00	N/A	N/A	N/A
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	118.70% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	54.00% Upside
VRNA Verona Pharma PLC American Depositary Share	3.00	Buy	$94.56	0.25% Upside

Current Analyst Ratings Breakdown

Latest CTIC, NUVL, CYTK, and VRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	VRNA Verona Pharma PLC American Depositary Share	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $138.00
6/18/2025	VRNA Verona Pharma PLC American Depositary Share	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$92.00 ➝ $116.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$95.00 ➝ $110.00
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
6/2/2025	VRNA Verona Pharma PLC American Depositary Share	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $90.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/14/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
5/13/2025	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $53.00
5/7/2025	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$82.00 ➝ $80.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTIC CTI BioPharma	$53M	22.62	N/A	N/A	($0.14) per share	-64.93
CYTK Cytokinetics	$18.47M	209.70	N/A	N/A	($1.15) per share	-28.20
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
VRNA Verona Pharma PLC American Depositary Share	$42.28M	189.91	N/A	N/A	$2.56 per share	36.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTIC CTI BioPharma	-$92.99M	-$0.58	N/A	26.74	N/A	-91.38%	N/A	-55.82%	N/A
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,144.00	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)

Latest CTIC, NUVL, CYTK, and VRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTIC CTI BioPharma	N/A	1.27	1.26
CYTK Cytokinetics	N/A	5.99	5.99
NUVL Nuvalent	N/A	14.48	14.48
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTIC CTI BioPharma	91.45%
CYTK Cytokinetics	N/A
NUVL Nuvalent	97.26%
VRNA Verona Pharma PLC American Depositary Share	85.88%

Insider Ownership

Company	Insider Ownership
CTIC CTI BioPharma	7.61%
CYTK Cytokinetics	2.70%
NUVL Nuvalent	10.20%
VRNA Verona Pharma PLC American Depositary Share	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTIC CTI BioPharma	127	131.88 million	121.84 million	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable

CTIC, NUVL, CYTK, and VRNA Headlines

Recent News About These Companies

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by PFG Investments LLC

June 22 at 4:23 AM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Price Target Raised to $138.00 at Wells Fargo & Company

June 21 at 1:57 AM | americanbankingnews.com

Roth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market Prospects

June 20 at 10:40 AM | msn.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given New $138.00 Price Target at Wells Fargo & Company

June 20 at 8:50 AM | marketbeat.com

Roth Capital Reiterates Buy Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 20 at 1:51 AM | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher Sells 80,000 Shares of Stock

June 19 at 7:06 AM | insidertrades.com

Mission Wealth Management LP Purchases New Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 19 at 4:02 AM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in Stock

June 18, 2025 | marketbeat.com

Verona Pharma: An Impressive Initial Launch

June 18, 2025 | seekingalpha.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth Capital

June 18, 2025 | marketbeat.com

Traders Purchase Large Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 17, 2025 | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?

June 16, 2025 | marketbeat.com

Traders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 16, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 400,000 Shares

June 16, 2025 | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CFO Sells $4,560,000.00 in Stock

June 16, 2025 | americanbankingnews.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 14, 2025 | finance.yahoo.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 14, 2025 | insidertrades.com

Cantor Fitzgerald Predicts Verona Pharma FY2025 Earnings

June 14, 2025 | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 13, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 400,000 Shares

June 13, 2025 | marketbeat.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 13, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTIC, NUVL, CYTK, and VRNA Company Descriptions

CTI BioPharma NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Cytokinetics NASDAQ:CYTK

$32.43 -0.30 (-0.92%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$32.28 -0.15 (-0.46%)

As of 06/20/2025 07:27 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Nuvalent NASDAQ:NUVL

$75.00 -0.53 (-0.70%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$74.99 -0.01 (-0.01%)

As of 06/20/2025 04:20 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$94.32 +3.40 (+3.74%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$94.38 +0.07 (+0.07%)

As of 06/20/2025 07:59 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time